National Cancer Institute (NCI)–designated cancer centers shape cancer care in the United States and are supported by substantial public funds (in fiscal year 2018, $330 million in core funding for 70 cancer centers).¹ Cancer care is also shaped by industry, because developing new cancer therapeutics represents a major market opportunity. Industry payments to academic physicians risk blurring the
... [Show full abstract] line between innovation and the evaluation of new therapies. We used Open Payments data from the Centers for Medicare & Medicaid Services (CMS) to examine industry payments made to physician directors of NCI-designated cancer centers.